

Simon Tremblay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7693852/publications.pdf>

Version: 2024-02-01

20
papers

456
citations

759233

12
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

760
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Immunosuppression for Liver Retransplantation: Babel Revisited. <i>Transplantation</i> , 2021, 105, 1658-1659. | 1.0 | 0 |
| 2 | Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells. <i>American Journal of Transplantation</i> , 2020, 20, 399-410. | 4.7 | 18 |
| 3 | A prospective, iterative, adaptive trial of carfilzomib-based desensitization. <i>American Journal of Transplantation</i> , 2020, 20, 411-421. | 4.7 | 47 |
| 4 | Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection. <i>Transplantation</i> , 2020, 104, 2403-2414. | 1.0 | 6 |
| 5 | Plasma cell targeting to prevent antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 33-41. | 4.7 | 16 |
| 6 | mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28 ^{hi} Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection. <i>Transplantation</i> , 2020, 104, 1058-1069. | 1.0 | 13 |
| 7 | Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. <i>American Journal of Transplantation</i> , 2019, 19, 3035-3045. | 4.7 | 44 |
| 8 | Discharge medication procurement and education after kidney transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13627. | 1.6 | 3 |
| 9 | Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients. <i>Pharmacotherapy</i> , 2019, 39, 564-575. | 2.6 | 2 |
| 10 | A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. <i>Clinical Transplantation</i> , 2018, 32, e13155. | 1.6 | 15 |
| 11 | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. <i>American Journal of Transplantation</i> , 2017, 17, 432-442. | 4.7 | 109 |
| 12 | Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1951-1953. | 6.1 | 14 |
| 13 | IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 1692-1694. | 27.0 | 14 |
| 14 | Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. <i>AAPS Journal</i> , 2017, 19, 1332-1347. | 4.4 | 15 |
| 15 | Reply to "Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View". <i>American Journal of Transplantation</i> , 2017, 17, 1693-1693. | 4.7 | 0 |
| 16 | Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. <i>PLoS Medicine</i> , 2017, 14, e1002428. | 8.4 | 29 |
| 17 | Successful Simultaneous Liver-Kidney Transplantation in the Presence of Multiple High-Titered Class I and II Antidonor HLA Antibodies. <i>Transplantation Direct</i> , 2016, 2, e121. | 1.6 | 17 |
| 18 | Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes. <i>Progress in Transplantation</i> , 2016, 26, 183-190. | 0.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Addition of Rifampin to Vancomycin for Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: What Is the Evidence?. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1045-1054. | 1.9 | 21 |
| 20 | Impact of a Pharmacist-Led Warfarin Self-Management Program on Quality of Life and Anticoagulation Control: A Randomized Trial. <i>Pharmacotherapy</i> , 2012, 32, 871-879. | 2.6 | 63 |